Literature DB >> 30196824

Fulminant Anti-GAD antibody encephalitis presenting with status epilepticus requiring aggressive immunosuppression.

J Triplett1, S Vijayan1, A MacDonald1, N Lawn1, A McLean-Tooke2, M Bynevelt3, C Phatouros3, T Chemmanam4.   

Abstract

Antibodies against glutamic acid decarboxylase (GAD) are reported in association with numerous neurological conditions including temporal lobe epilepsy and limbic encephalitis. We report a case of Anti-GAD-Antibody associated encephalitis presenting with epilepsia partialis continua (EPC) progressing to a fulminant encephalopathy preferentially affecting the frontal lobes associated with coma and refractory status epilepticus. The abnormalities identified on MRI included marked bilateral frontal lobe involvement which has not been reported in other auto-immune encephalitides and may be specific for Anti-GAD-Antibody associated encephalitis. Similar to the majority of cases of Anti-GAD associated neurological disturbance no underlying malignancy was identified. Treatment with high dose corticosteriods, IVIG and plasmapheresis had minimal response, but escalation of treatment with rituximab and cyclophosphamide was associated with clinical improvement, reducing antibody titers and resolution of MRI changes.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmune encephalitis; Cyclophosphamide; Epilepsia partialis continua; Glutamic acid decarboxylase (GAD) antibodies; Rituximab

Mesh:

Substances:

Year:  2018        PMID: 30196824     DOI: 10.1016/j.jneuroim.2018.06.013

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  4 in total

Review 1.  Neurological Syndromes Associated with Anti-GAD Antibodies.

Authors:  Maëlle Dade; Giulia Berzero; Cristina Izquierdo; Marine Giry; Marion Benazra; Jean-Yves Delattre; Dimitri Psimaras; Agusti Alentorn
Journal:  Int J Mol Sci       Date:  2020-05-24       Impact factor: 5.923

2.  An Evidence-Based Approach to Diagnosis and Prognosis in a Young Woman with New-Onset Super-Refractory Status Epilepticus: A Case Report.

Authors:  Pallavi Juneja; Dionne Swor
Journal:  Case Rep Neurol       Date:  2022-01-17

Review 3.  Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies.

Authors:  Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2022-01-27       Impact factor: 6.088

Review 4.  [Pharmacotherapy and intensive care aspects of status epilepticus: update 2020/2021].

Authors:  Gabrielė Saitov; Annekatrin Müller; Börge Bastian; Dominik Michalski
Journal:  Anaesthesist       Date:  2021-07-01       Impact factor: 1.041

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.